Therapeutics Company Reveals Positive Data From Cancer Clinical Study

CX-904 showcased a favorable safety profile, a critical factor in the administration and monitoring of patients in outpatient settings.

CytomX Therapeutics, Inc. (Nasdaq: CTMX) unveiled positive initial data from its ongoing CX-904 Phase 1a dose escalation clinical study. This pivotal study is centered around CX-904, an investigational PROBODY® T-cell engager that is both masked and conditionally activated, designed to target the epidermal growth factor receptor (EGFR) on cancer cells a…